Monitor upcoming revumenib data readouts in Q4 2026 (frontline combinations, post-transplant maintenance) and the initiation of the RAVEN and MenTain trials, as these will shape the frontline opportunity and long-term growth trajectory.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 2 $14.29entry
- T+1 · 3d ago −26.87%α −28.52% · $10.45
- T+3 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 25d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Syndax reported Q3 2026 total revenue of $83.3M, beating the $81.8M consensus, driven by Revuforj net revenue of $60.7M (+90% YoY) and Niktimvo collaboration revenue of $22.6M. EPS of -$0.55 missed the consensus estimate of -$0.48. The company maintained full-year 2026 operating expense guidance of ~$400M and expects to reach profitability with its current cash and anticipated revenue.
Key Financial Metrics
Key Facts
- Total revenue of $83.3M in Q3 2026, an 82% year-over-year increase, above the $81.8M consensus.
- Revuforj net revenue of $60.7M, up 90% YoY and 11% QoQ; new patients grew 20% QoQ.
- Niktimvo net revenue of $67.4M (recorded by Incyte), resulting in Syndax collaboration revenue of $22.6M.
- GAAP net loss of $49.4M or $0.55 per share, compared to consensus EPS of -$0.48 (miss).
- Cash, cash equivalents, and investments of $551.1M as of September 30, 2026.
- Full-year 2026 R&D plus SG&A expenses expected to be approximately $400M, excluding $50M in non-cash stock compensation.
- CFO transition announced: Keith Goldan retiring, Aaron A. Ondrey appointed effective November 9, 2026.
- MAXPIRe Phase 2 trial of axatilimab in IPF did not meet primary endpoint; no further development in IPF planned.
Financial Impact
Revenue beat consensus by ~1.8% ($83.3M vs $81.8M); EPS miss of $0.55 vs $0.48 consensus (14.6% miss).
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Revuforj product revenue | $60.7M | +90.0% |
| Niktimvo collaboration revenue | $22.6M | +63.0% |
Risk Factors
- EPS miss of 14.6% vs consensus may pressure the stock near-term.
- MAXPIRe IPF trial failure removes a potential pipeline expansion opportunity for axatilimab.
- Dependence on successful frontline trial data to unlock the multi-billion-dollar menin inhibitor opportunity.
- CFO transition introduces near-term leadership uncertainty.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3393699 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Nov 2, 2026 3d ago | 8-K | No price | awaiting T+60 | awaiting T+60 | No price |
Nov 2, 2026 3d ago | Press Release | No price | awaiting T+60 | awaiting T+60 | No price |
Nov 2, 2026 3d ago | Press Release | $14.29 | awaiting T+60 | awaiting T+60 | $9.37 (−34.43%) |
Oct 29, 2026 7d ago | 144 | $13.65 | awaiting T+60 | awaiting T+60 | $9.37 (−31.36%) |
Jul 14, 2026 16w ago | 8-K | $24.13 $17.03 | ▼ −29.42% | ▼ −32.80% | $9.37 (−61.17%) |
Jul 1, 2026 18w ago | Press Release | $21.82 $18.20 | ▼ −16.59% | ▼ −20.16% | $9.37 (−57.06%) |
Jun 11, 2026 21w ago | Press Release | $17.91 $20.56 | ▲ +14.80% | ▲ +10.40% | $9.37 (−47.68%) |
Jun 10, 2026 21w ago | 8-K | $17.91 $20.56 | ▲ +14.80% | ▲ +10.40% | $9.37 (−47.68%) |
Jun 4, 2026 22w ago | Press Release | $17.34 $19.29 | ▲ +11.25% | ▲ +7.25% | $9.37 (−45.96%) |
Jun 4, 2026 22w ago | DEFA14A | $18.02 $19.54 | ▲ +8.44% | ▲ +6.55% | $9.37 (−48.00%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers